At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 10 enrolled
Drug / intervention
Deferasiroxdrug
Likely dose
Deferasirox 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda
University of Texas Southwestern Medical Center·interventional·Posted Jan 23, 2008·Updated Feb 10, 2014
In Brief
A Phase 3 clinical trial evaluating Deferasirox for Porphyria Cutanea Tarda. Completed, enrolled 10 participants across 1 site.
Detailed Summary
To determine the efficacy and tolerability of deferasirox in the treatment of Porphyria Cutanea Tarda. Primary objective - the elimination of all blistering within 6 months of treatment. Secondary objective - decrease in total body iron levels.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPorphyria Cutanea Tarda
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedJan 2008
Primary CompletionApr 2010
TodayJul 2026
First PostedJan 23, 2008
Enrollment StartJan 1, 2008
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.4 years ago
Interventions
Deferasiroxdrug
250 mg of deferasirox once daily for 6 months